(120 days)
Not Found
No
The device description focuses on electrical stimulation parameters and hardware components. There is no mention of AI/ML algorithms for data analysis, treatment personalization, or any other function.
Yes.
The device is a percutaneous electrical nerve stimulator (PENS) system indicated for symptomatic relief of post-operative pain, which directly implies a therapeutic function.
No
This device is a percutaneous electrical nerve stimulator (PENS) system used for symptomatic relief of post-operative pain, not for diagnosing conditions.
No
The device description explicitly states it is a "wearable, battery-operated device" that administers electrical pulses through "wire assembly and stimulation needles" powered by "three zinc air batteries." This clearly indicates the presence of hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information about a person's health. This testing is done outside of the body ("in vitro").
- Device Function: The Primary Relief device is a percutaneous electrical nerve stimulator. It works by applying electrical pulses directly to the patient's ear to relieve pain. This is a therapeutic intervention performed on the body, not a diagnostic test performed on a specimen.
- Intended Use: The intended use is for "symptomatic relief of post-operative pain." This is a treatment indication, not a diagnostic indication.
- Device Description: The description details the electrical stimulation mechanism and how it's applied to the ear, not how it analyzes biological samples.
Therefore, the Primary Relief device falls under the category of a therapeutic medical device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Primary Relief is a percutaneous electrical nerve stimulator (PENS) system indicated for up to 3 days for symptomatic relief of post-operative pain following cesarean section delivery or up to 3 days adjunctive symptomatic relief of post-operative pain following cardiac surgery.
Product codes (comma separated list FDA assigned to the subject device)
NHI
Device Description
The Primary Relief is designed to aid in the reduction of post-operative pain by the method of cranial electrical stimulation at the auricular stimulation points. The Primary Relief is a wearable, battery-operated device that is designed to administer periodical low level electrical pulses to the ear over three days / 72 hours from the time of activation of the device.
The electrical pulse from the device will be delivered to the branches of cranial nerves on the ear through a set of wire assembly and stimulation needles. Three zinc air batteries with 1.4 V each provide the required stimulation energy for 72 hours. There stimulation electrode and one ground electrode which constitute of a needle and lead/ wire with the snap-fit ring. The stimulation needles are inserted at three specific points, which have the ability to stimulate the cranial nerves.
The ground electrode is inserted at one specific point (constant in all treatments) which forms the functional earthing to the device. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the stimulation pattern consists of rectangular pulses with differing inter-pulse intervals.
A 3-pin connector is provided, which is used to check the output voltage of the device once it is activated and before applying to the patient with any one of the voltage measuring devices available in the market with the appropriate regulatory compliance.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Ear
Indicated Patient Age Range
Adults
Intended User / Care Setting
Clinics, Hospital and Home environments, Prescription Use (Part 21 CFR 801 Subpart D) by or on the order of a licensed healthcare practitioner.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
This was a single center, double arm, randomized, double-blinded prospective study involving 60 subjects who have undergone elective cardiac surgery and satisfied all the inclusion criteria. The subjects were split into the intervention group (29 patients: mean age = 53.86 ± 11.3 years) who received the Primary Relief device (Group A - treatment arm) and the control group (mean age = 54.90 ± 9.2 years) who received the sham device (Group B - identical to the subject device but delivers no stimulation and acts as placebo). The subject and sham devices were placed on the patients post-operatively prior to being awoken from anesthesia. Analgesics were administered upon patients' request to both treatment and control groups.
The primary efficacy endpoint is pain intensity at rest and on cough (measured through NRS -Numeric Rating Scale of 11 points with 0 signifying no pain and 10 being the worst pain imaginable) and the secondary efficacy endpoints included five measures intended to assess the pulmonary function. Post-operative baseline pain scores were obtained at 6-8 hours following placement of the subject and sham devices upon waking of the subjects from anesthesia. The primary and secondary endpoints were measured according to validated and widely used tools at 9 intervals spanning 72 hours.
The analysis showed that minimally invasive percutaneous electrical nerve stimulation treatment using Primary Relief device reduces the pain score compared to that of the control group:
- On average, the Group A score was 1.19 units (SE=0.16; P-value
§ 882.5890 Transcutaneous electrical nerve stimulator for pain relief.
(a)
Identification. A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
September 13, 2022
DyAnsys, Inc. Srini Nageshwar CEO 300, North Bayshore Boulevard San Mateo. California 94401
Re: K221425
Trade/Device Name: Primary Relief Regulation Number: 21 CFR 882.5890 Regulation Name: Transcutaneous Electrical Nerve Stimulator For Pain Relief Regulatory Class: Class II Product Code: NHI Dated: August 9, 2022 Received: August 11, 2022
Dear Srini Nageshwar:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Amber Ballard, PhD Assistant Director DHT5B: Division of Neuromodulation and Physical Medicine Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K221425
Device Name Primary Relief
Indications for Use (Describe)
The Primary Relief is a percutaneous electrical nerve stimulator (PENS) system indicated for up to 3 days for symptomatic relief of post-operative pain following cesarean section delivery or up to 3 days adjunctive symptomatic relief of post-operative pain following cardiac surgery.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for DyAnsys. The logo consists of a stylized red symbol to the left of the word "DyAnsys" in black font. A circled "R" symbol is located to the upper right of the word "DyAnsys", indicating that the name is a registered trademark.
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of 21 CFR 807.87 and 21 CFR 807.92.
510(k) Number: K221425
I. SUBMITTER
| Date Prepared: | September 13, 2022 |
|---|---|
| Name: | DyAnsys, Inc |
| Address: | 300, North Bayshore Boulevard, |
| San Mateo, CA 94401, USA | |
| Contact Person: | Srini Nageshwar |
| Phone Number: | 408.480.4700 |
| Facsimile Number: | (650)-556-1621 |
II. DEVICE INFORMATION
| Trade Name: | Primary Relief |
|---|---|
| Classification Name: | Percutaneous Electrical Nerve Stimulation (PENS) device |
| (21 CFR 882.5890) | |
| Device Class: | Class II |
| Product Code: | NHI |
III. PREDICATE DEVICE INFORMATION
Model Name: Primary Relief (K213188) Manufacturer: DyAnsys, Inc. Classification Name: Percutaneous Electrical Nerve Stimulation (PENS) devices (21 CFR 882.5890) Device Class: Class II Product Code: NHI
The predicate device has not been subject to a design-related recall.
IV. DEVICE DESCRIPTION
The Primary Relief is designed to aid in the reduction of post-operative pain by the method of cranial electrical stimulation at the auricular stimulation points. The Primary Relief is a wearable, battery-operated device that is designed to administer periodical low level electrical pulses to the ear over three days / 72 hours from the time of activation of the device.
The electrical pulse from the device will be delivered to the branches of cranial nerves on the ear through a set of wire assembly and stimulation needles. Three zinc air batteries with 1.4 V each provide the required stimulation energy for 72 hours. There stimulation electrode and one ground electrode which constitute of a needle and lead/ wire with the snap-fit ring. The stimulation needles are inserted at three specific points, which have the ability to stimulate the cranial nerves.
4
Image /page/4/Picture/0 description: The image shows the logo for DyAnsys. The logo consists of a stylized red symbol resembling an arrow or abstract shape, followed by the company name "DyAnsys" in bold, black font. A registered trademark symbol is placed to the upper right of the company name.
The ground electrode is inserted at one specific point (constant in all treatments) which forms the functional earthing to the device. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the stimulation pattern consists of rectangular pulses with differing inter-pulse intervals.
A 3-pin connector is provided, which is used to check the output voltage of the device once it is activated and before applying to the patient with any one of the voltage measuring devices available in the market with the appropriate regulatory compliance
V. INDICATIONS FOR USE
The Primary Relief is a percutaneous electrical nerve stimulator (PENS) system indicated for up to 3 days for symptomatic relief of post-operative pain following cesarean section delivery or up to 3 days adjunctive symptomatic relief of post-operative pain following cardiac surgery..
The Indications for Use statement of Primary Relief is not identical to that of the predicate device; The only difference is the expansion in indications for use which is adequately supported through the clinical study results. The difference does not alter the intended therapeutic use of the device nor do they affect the safety and effectiveness of the device relative to the predicate. Both the subject and predicate devices have the same intended use of symptomatic relief and management of pain through the delivery of short-term electrical stimulation.
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
The DyAnsys, Inc Primary Relief system is substantially equivalent to the legally marketed predicate device Primary Relief(K213188). It was evaluated through performance and non-clinical testing.
| MODEL NAME | Primary Relief
(Subject) | Primary Relief
(K213188 - Predicate) |
|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MANUFACTURER | DyAnsys Inc. | DyAnsys Inc. |
| Intended Use / Indications for Use Statement | | |
| INDICATIONS FOR USE | The Primary Relief is a
percutaneous electrical nerve
stimulator (PENS) system
indicated for up to 3 days for
symptomatic relief of post-
operative pain following cesarean
section delivery or up to 3 days
adjunctive symptomatic relief of
post-operative pain following
cardiac surgery. | The Primary Relief is a
percutaneous electrical nerve
stimulator (PENS) system
indicated for up to 3 days for
symptomatic relief of post-
operative pain following
cesarean section delivery. |
| PATIENT POPULATION | Adults | Adults |
Table 6.1: Comparison of Technological Characteristics
5
Image /page/5/Picture/0 description: The image shows the logo for DyAnsys. The logo consists of a stylized red symbol resembling an arrow pointing to the right, followed by the text "DyAnsys" in black. A registered trademark symbol is present to the upper right of the text.
| SINGLE USE
| ELECTRODES | Yes | Yes |
|---|---|---|
| PORTABLE COMPONENTS | Yes | Yes |
6
Image /page/6/Picture/0 description: The image contains the logo for DyAnsys. The logo consists of a stylized red symbol resembling an arrow or a waveform, followed by the text "DyAnsys" in a clean, sans-serif font. A registered trademark symbol is placed to the upper right of the word "DyAnsys".
| TECHNOLOGICAL CHARACTERISTICS | ||
|---|---|---|
| PULSE GENERATOR | ||
| PRODUCT DIMENSION | ||
| (mm) | 50 * 23 * 7 | 50 * 23 * 7 |
| MASS (g) | 8 g (including battery) | 8 g (including battery) |
| PRODUCT SHAPE | Rectangle | Rectangle |
| POWER | ||
| FREQUENCY (Hz) | 1 - 100 (Sweep Pattern) | 1 - 100 (Sweep Pattern) |
| WAVEFORM | Biphasic with | |
| Rectangular Pulse | Biphasic with | |
| Rectangular Pulse | ||
| BATTERY TYPE | P13 Zinc Air batteries that are non- | |
| rechargeable | P13 Zinc Air batteries | |
| BATTERY CAPACITY | 310 mAh | 310 mAh |
| NO. x VOLTAGE (V) | 3 x 1.4 V | 3 x 1.4 V |
| PULSE WIDTH (ms) | ~ 0.980 | ~ 0.980 |
| DUTY CYCLE | Continuous Stimulation | Continuous Stimulation |
| TYPICAL BATTERY | ||
| OPERATING TIME (hours) | 72 | 72 |
| ENVIRONMENTAL | ||
| OPERATING | ||
| TEMPERATURE | 5 °C to 45 °C | Not publicly available |
| OPERATING HUMIDITY | 40% to 80% | Not publicly available |
| ENVIRONMENT OF USE | Clinics, Hospital and Home | |
| environments | Clinics, Hospital and Home | |
| environments | ||
| STERILIZATION OF | ||
| ELECTRODES | EtO Sterilization | EtO Sterilization |
| RE-USE | Single use Device | Single use Device |
| SHELF LIFE | 6 months | 6 months |
| ACCESSORIES | - Primary Relief with non activated batteries |
- Top Cover of Primary Relief
- Sterile pack of needles for use with the Primary Relief device
- Adhesive to fasten the needles
- Adhesive for the Primary Relief device | Not publicly available |
7
Image /page/7/Picture/0 description: The image shows the logo for DyAnsys. The logo consists of a stylized red symbol resembling an arrow pointing upwards, followed by the text "DyAnsys" in black font. A circled "R" symbol, indicating a registered trademark, is positioned to the upper right of the text.
Table 6.2: Comparison of System Characteristics
| System Characteristic | Primary Relief
(Subject) | Primary Relief
(K213188 - Predicate) |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PULSE GENERATOR | | |
| Software Controlled | Yes | Yes |
| Mass (g) | 8 g | 8 g |
| Dimensions(mm) | 50 * 23 * 7 | 50 * 23 * 7 |
| Housing Material | ABS Plastic Material | ABS Plastic Material |
| ELECTRODE NEEDLE ARRAYS | | |
| Introduction Method | Percutaneous | Percutaneous |
| Electrode Configuration | Single needle in all the 4 leads | Single needle in all the 4 leads |
| Tissue Contact | Skin/Tissue | Skin/Tissue |
| Electrode Type | Percutaneous fine needle | Percutaneous fine needle |
| Stimulating
Electrode Material | Titanium | Titanium |
| Stimulating
Electrode Shape | Straight | Straight |
| Number of leads | 4 (3 signal and 1 ground) | 4 (3 signal and 1 ground) |
| Needle Dimensions -
Diameter (mm) x
Length (mm) | 0.4 x 2 | 0.4 x 2 |
| Surface area of
needle (cm2) | 0.0201 cm2 | 0.0201 cm2 |
| Supplied Sterile | Yes | Yes |
| SYSTEM CHARACTERISTICS (OUTPUT SPECS) | | |
| Net Charge
(microcoulomb (µC) per
pulse; | 0 (Due to biphasic nature of the
waveform) | Not publicly available |
| Where and how it is
used | Low levels of electrical current are
delivered by the external
stimulator through electrodes
placed percutaneously on the ear to
target the associated cranial and
occipital nerves. | Low levels of electrical current are
delivered by the external stimulator
through electrodes placed
percutaneously on the ear to target
the associated cranial and occipital
nerves. |
| Anodes / Cathodes
please identify the
ground | The ground electrode of Primary
Relief is a single isolated wire
separated from the assembly of
signal wires, which creates a
closed circuit for safe and proper
functioning of stimulation device. | The ground electrode of Primary
Relief is a single isolated wire
separated from the assembly of
signal wires, which creates a closed
circuit for safe and proper
functioning of stimulation device. |
8
Image /page/8/Picture/0 description: The image shows the logo for DyAnsys. The logo consists of a red and black abstract symbol on the left, followed by the text "DyAnsys" in black. A registered trademark symbol is located to the upper right of the text.
The subject device. Primary Relief, has identical intended use, form factor, technological characteristics, mechanism of action and operating principles compared to that of the predicate device. Both devices are intended to be a prescription (Rx) devices for use by or on the order of a licensed healthcare practitioner. Both devices are body-worn, have similar indications for use and deliver electrical stimulation therapy for symptomatic relief and management of post-operative pain. Both devices deliver biphasic electrical stimulation waveforms hence are charge balanced due to the a positive and negative phase between active electrode(s) and the ground electrode.
The purpose of this submission is to expand the indications of use to include adjunctive use in patients with post- operative pain following cardiac surgery along with the already 510(k) cleared indication for post- operative pain following cesarean section delivery (K213188). The electrical stimulation parameters and the other characteristics remain identical to the predicate device.
The results from the clinical study (summarized below) have demonstrated the safety of the therapy and there were no serious adverse events observed during the study period.
VII. Performance Data
The nonclinical testing of Primary Relief device included biocompatibility testing, electrical safety (electromagnetic compatibility and safety), performance bench testing and software verification and validation.
The Primary Relief device and its components are subjected to performance bench testing to validate the effectiveness of each unit. The final product testing is performed to verify and compare the effectual output along with that of the predicate device. The functional test is performed for 72 hours to monitor the continuous performance. The pulse duration, amplitude and current values are captured for the Primary Relief device. The Primary Relief has equivalent performance specifications when compared to the predicate device.
Clinical testing results presented with this submission have demonstrated the safety of the therapy. No serious adverse events were observed during the study.
9
Image /page/9/Picture/0 description: The image shows the logo for DyAnsys, a medical device company. The logo consists of a stylized red symbol resembling an abstract letter 'A' or an arrow pointing upwards, followed by the company name "DyAnsys" in black, sans-serif font. A registered trademark symbol is placed to the upper right of the company name.
VIII. Summary of Clinical Information
This was a single center, double arm, randomized, double-blinded prospective study involving 60 subjects who have undergone elective cardiac surgery and satisfied all the inclusion criteria. The subjects were split into the intervention group (29 patients: mean age = 53.86 ± 11.3 vears) who received the Primary Relief device (Group A - treatment arm) and the control group (mean age = 54.90 ± 9.2 years) who received the sham device (Group B - identical to the subject device but delivers no stimulation and acts as placebo). The subject and sham devices were placed on the patients post-operatively prior to being awoken from anesthesia. Analgesics were administered upon patients' request to both treatment and control groups.
The primary efficacy endpoint is pain intensity at rest and on cough (measured through NRS -Numeric Rating Scale of 11 points with 0 signifying no pain and 10 being the worst pain imaginable) and the secondary efficacy endpoints included five measures intended to assess the pulmonary function. Post-operative baseline pain scores were obtained at 6-8 hours following placement of the subject and sham devices upon waking of the subjects from anesthesia. The primary and secondary endpoints were measured according to validated and widely used tools at 9 intervals spanning 72 hours.
The analysis showed that minimally invasive percutaneous electrical nerve stimulation treatment using Primary Relief device reduces the pain score compared to that of the control group :
- · On average, the Group A score was 1.19 units (SE=0.16; P-value